Hubbry Logo
Menstrual cycleMenstrual cycleMain
Open search
Menstrual cycle
Community hub
Menstrual cycle
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Menstrual cycle
Menstrual cycle
Menstrual cycle
View on Wikipedia
from Wikipedia

Menstrual cycle

The menstrual cycle is a series of natural changes in hormone production and the structures of the uterus and ovaries of the female reproductive system that makes pregnancy possible. The ovarian cycle controls the production and release of eggs and the cyclic release of estrogen and progesterone. The uterine cycle governs the preparation and maintenance of the lining of the uterus (womb) to receive an embryo. These cycles are concurrent and coordinated, normally last between 21 and 35 days, with a median length of 28 days. Menarche (the onset of the first period) usually occurs around the age of 12 years; menstrual cycles continue for about 30–45 years.

Naturally occurring hormones drive the cycles; the cyclical rise and fall of the follicle stimulating hormone prompts the production and growth of oocytes (immature egg cells). The hormone estrogen stimulates the uterus lining (endometrium) to thicken to accommodate an embryo should fertilization occur. The blood supply of the thickened lining provides nutrients to a successfully implanted embryo. If implantation does not occur, the lining breaks down and blood is released. Triggered by falling progesterone levels, menstruation (commonly referred to as a "period") is the cyclical shedding of the lining, and is a sign that pregnancy has not occurred.

Each cycle occurs in phases based on events either in the ovary (ovarian cycle) or in the uterus (uterine cycle). The ovarian cycle consists of the follicular phase, ovulation, and the luteal phase; the uterine cycle consists of the menstrual, proliferative and secretory phases. Day one of the menstrual cycle is the first day of the period, which lasts for about 5 days. Around day fourteen, an egg is usually released from the ovary.

The menstrual cycle can cause some women to experience premenstrual syndrome with symptoms that may include tender breasts, and tiredness. More severe symptoms that affect daily living are classed as premenstrual dysphoric disorder, and are experienced by 3–8% of women. During the first few days of menstruation some women experience period pain that can spread from the abdomen to the back and upper thighs. The menstrual cycle can be modified by hormonal birth control.

Cycles and phases

[edit]
Progression of the menstrual cycle and some of the hormones contributing to it

The menstrual cycle encompasses the ovarian and uterine cycles. The ovarian cycle describes changes that occur in the follicles of the ovary,[1] whereas the uterine cycle describes changes in the endometrial lining of the uterus. Both cycles can be divided into phases. The ovarian cycle consists of alternating follicular and luteal phases, and the uterine cycle consists of the menstrual phase, the proliferative phase, and the secretory phase.[2] The menstrual cycle is controlled by the hypothalamus in the brain, and the anterior pituitary gland at the base of the brain. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which causes the nearby anterior pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Before puberty, GnRH is released in low steady quantities and at a steady rate. After puberty, GnRH is released in large pulses, and the frequency and magnitude of these determine how much FSH and LH are produced by the pituitary.[3]

Measured from the first day of one menstruation to the first day of the next, the length of a menstrual cycle varies but has a median length of 28 days.[4] The cycle is often less regular at the beginning and end of a woman's reproductive life.[4] At puberty, a child's body begins to mature into an adult body capable of sexual reproduction; the first period (called menarche) occurs at around 12 years of age and continues for about 30–45 years.[5][6] Menstrual cycles end at menopause, which is usually between 45 and 55 years of age.[7][8]

Ovarian cycle

[edit]

Between menarche and menopause the ovaries regularly alternate between luteal and follicular phases during the monthly menstrual cycle.[9] Stimulated by gradually increasing amounts of estrogen in the follicular phase, discharges of blood flow stop and the uterine lining thickens. Follicles in the ovary begin developing under the influence of a complex interplay of hormones, and after several days one, or occasionally two, become dominant, while non-dominant follicles shrink and die. About mid-cycle, some 10–12 hours after the increase in luteinizing hormone, known as the LH surge,[4] the dominant follicle releases an oocyte, in an event called ovulation.[10]

After ovulation, the oocyte lives for 24 hours or less without fertilization,[11] while the remains of the dominant follicle in the ovary become a corpus luteum – a body with the primary function of producing large amounts of the hormone progesterone.[12][a] Under the influence of progesterone, the uterine lining changes to prepare for potential implantation of an embryo to establish a pregnancy. The thickness of the endometrium continues to increase in response to mounting levels of estrogen, which is released by the antral follicle (a mature ovarian follicle) into the blood circulation. Peak levels of estrogen are reached at around day thirteen of the cycle and coincide with ovulation. If implantation does not occur within about two weeks, the corpus luteum degenerates into the corpus albicans, which does not produce hormones, causing a sharp drop in levels of both progesterone and estrogen. This drop causes the uterus to lose its lining in menstruation; it is around this time that the lowest levels of estrogen are reached.[14]

In an ovulatory menstrual cycle, the ovarian and uterine cycles are concurrent and coordinated and last between 21 and 35 days, with a population average of 27–29 days.[15] Although the average length of the human menstrual cycle is similar to that of the lunar cycle, there is no causal relation between the two.[16]

Follicular phase

[edit]
Main article: Follicular phase

The ovaries contain a finite number of egg stem cells, granulosa cells and theca cells, which together form primordial follicles.[12] At around 20 weeks into gestation some 7 million immature eggs have already formed in an ovary. This decreases to around 2 million by the time a girl is born, and 300,000 by the time she has her first period. On average, one egg matures and is released during ovulation each month after menarche.[17] Beginning at puberty, these mature to primary follicles independently of the menstrual cycle.[18] The development of the egg is called oogenesis and only one cell survives the divisions to await fertilization. The other cells are discarded as polar bodies, which cannot be fertilized.[19] The follicular phase is the first part of the ovarian cycle and it ends with the completion of the antral follicles.[9] Meiosis (cell division) remains incomplete in the egg cells until the antral follicle is formed. During this phase usually only one ovarian follicle fully matures and gets ready to release an egg.[20] The follicular phase shortens significantly with age, lasting around 14 days in women aged 18–24 compared with 10 days in women aged 40–44.[14]

Through the influence of a rise in follicle stimulating hormone (FSH) during the first days of the cycle, a few ovarian follicles are stimulated. These follicles, which have been developing for the better part of a year in a process known as folliculogenesis, compete with each other for dominance. All but one of these follicles will stop growing, while one dominant follicle – the one that has the most FSH receptors – will continue to maturity. The remaining follicles die in a process called follicular atresia.[21] Luteinizing hormone (LH) stimulates further development of the ovarian follicle. The follicle that reaches maturity is called an antral follicle, and it contains the ovum (egg cell).[22]

The theca cells develop receptors that bind LH, and in response secrete large amounts of androstenedione. At the same time the granulosa cells surrounding the maturing follicle develop receptors that bind FSH, and in response start secreting androstenedione, which is converted to estrogen by the enzyme aromatase. The estrogen inhibits further production of FSH and LH by the pituitary gland. This negative feedback regulates levels of FSH and LH. The dominant follicle continues to secrete estrogen, and the rising estrogen levels make the pituitary more responsive to GnRH from the hypothalamus. As estrogen increases this becomes a positive feedback signal, which makes the pituitary secrete more FSH and LH. This surge of FSH and LH usually occurs one to two days before ovulation and is responsible for stimulating the rupture of the antral follicle and release of the oocyte.[18][23]

Ovulation

[edit]
Main article: Ovulation
An ovary about to release an egg

Around day fourteen, the egg is released from the ovary.[24] Called ovulation, this occurs when a mature egg is released from the ovarian follicles into the pelvic cavity and enters the fallopian tube, about 10–12 hours after the peak in LH surge.[4] Typically only one of the 15–20 stimulated follicles reaches full maturity, and just one egg is released.[25] Ovulation only occurs in around 10% of cycles during the first two years following menarche, and by the age of 40–50, the number of ovarian follicles is depleted.[26] LH initiates ovulation at around day 14 and stimulates the formation of the corpus luteum.[2] Following further stimulation by LH, the corpus luteum produces and releases estrogen, progesterone, relaxin (which relaxes the uterus by inhibiting contractions of the myometrium), and inhibin (which inhibits further secretion of FSH).[27]

The release of LH matures the egg and weakens the follicle wall in the ovary, causing the fully developed follicle to release its oocyte.[28] If it is fertilized by a sperm, the oocyte promptly matures into an ootid, which blocks the other sperm cells and becomes a mature egg. If it is not fertilized by a sperm, the oocyte degenerates. The mature egg has a diameter of about 0.1 mm (0.0039 in),[29] and is the largest human cell.[30]

Which of the two ovaries – left or right – ovulates appears random;[31] no left and right coordinating process is known.[32] Occasionally both ovaries release an egg; if both eggs are fertilized, the result is fraternal twins.[33] After release from the ovary into the pelvic cavity, the egg is swept into the fallopian tube by the fimbria – a fringe of tissue at the end of each fallopian tube. After about a day, an unfertilized egg disintegrates or dissolves in the fallopian tube, and a fertilized egg reaches the uterus in three to five days.[34]

Fertilization usually takes place in the ampulla, the widest section of the fallopian tubes. A fertilized egg immediately starts the process of embryonic development. The developing embryo takes about three days to reach the uterus, and another three days to implant into the endometrium. It has reached the blastocyst stage at the time of implantation: this is when pregnancy begins.[35] The loss of the corpus luteum is prevented by fertilization of the egg. The syncytiotrophoblast (the outer layer of the resulting embryo-containing blastocyst that later becomes the outer layer of the placenta) produces human chorionic gonadotropin (hCG), which is very similar to LH and preserves the corpus luteum. During the first few months of pregnancy, the corpus luteum continues to secrete progesterone and estrogens at slightly higher levels than those at ovulation. After this and for the rest of the pregnancy, the placenta secretes high levels of these hormones – along with hCG, which stimulates the corpus luteum to secrete more progesterone and estrogens, blocking the menstrual cycle.[36] These hormones also prepare the mammary glands for milk[b] production.[36]

Luteal phase

[edit]
Main article: Luteal phase

Lasting about 14 days,[4] the luteal phase is the final phase of the ovarian cycle and it corresponds to the secretory phase of the uterine cycle. During the luteal phase, the pituitary hormones FSH and LH cause the remaining parts of the dominant follicle to transform into the corpus luteum, which produces progesterone.[38][c] The increased progesterone starts to induce the production of estrogen. The hormones produced by the corpus luteum also suppress production of the FSH and LH that the corpus luteum needs to maintain itself. The level of FSH and LH fall quickly, and the corpus luteum atrophies.[40] Falling levels of progesterone trigger menstruation and the beginning of the next cycle. For an individual woman, the follicular phase often varies in length from cycle to cycle; by contrast, the length of her luteal phase will be fairly consistent from cycle to cycle at 10 to 16 days (average 14 days).[14]

Uterine cycle

[edit]
The anatomy of the uterus

The uterine cycle has three phases: menses, proliferative and secretory.[41]

Menstruation

[edit]
Main article: Menstruation

Menstruation (also called menstrual bleeding, menses or a period) is the first and most evident phase of the uterine cycle and first occurs at puberty. Called menarche, the first period occurs at the age of around twelve or thirteen years.[8] The average age is generally later in the developing world and earlier in the developed world.[42] In precocious puberty, it can occur as early as age eight years,[43] and this can still be normal.[44][45]

Menstruation is initiated each month by falling levels of estrogen and progesterone and the release of prostaglandins,[20] which constrict the spiral arteries. This causes them to spasm, contract and break up.[46] The blood supply to the endometrium is cut off and the cells of the top layer of the endometrium (the stratum functionalis) become deprived of oxygen and die. Later the whole layer is lost and only the bottom layer, the stratum basalis, is left in place.[20] An enzyme called plasmin breaks up the blood clots in the menstrual fluid, which eases the flow of blood and broken down lining from the uterus.[47] The flow of blood continues for 2–6 days and around 30–60 milliliters of blood is lost,[15] and is a sign that pregnancy has not occurred.[48]

The flow of blood normally serves as a sign that a woman has not become pregnant, but this cannot be taken as certainty, as several factors can cause bleeding during pregnancy.[49] Menstruation occurs on average once a month from menarche to menopause, which corresponds with a woman's fertile years. The average age of menopause in women is 52 years, and it typically occurs between 45 and 55 years of age.[50] Menopause is preceded by a stage of hormonal changes called perimenopause.[7]

Eumenorrhea denotes normal, regular menstruation that lasts for around the first five days of the cycle.[24] Women who experience menorrhagia (heavy menstrual bleeding) are more susceptible to iron deficiency than the average person.[51]

Proliferative phase

[edit]
During the menstrual cycle, levels of estradiol (an estrogen) vary by 200 percent. Levels of progesterone vary by over 1200 percent.[52]

The proliferative phase is the second phase of the uterine cycle when estrogen causes the lining of the uterus to grow and proliferate.[40] The latter part of the follicular phase overlaps with the proliferative phase of the uterine cycle.[31] As they mature, the ovarian follicles secrete increasing amounts of estradiol, an estrogen. The estrogens initiate the formation of a new layer of endometrium in the uterus with the spiral arterioles.[2]

As estrogen levels increase, cells in the cervix produce a type of cervical mucus[53] that has a higher pH and is less viscous than usual, rendering it more friendly to sperm.[54] This increases the chances of fertilization, which occurs around day 11 to day 14.[11] This cervical mucus can be detected as a vaginal discharge that is copious and resembles raw egg whites.[55] For women who are practicing fertility awareness, it is a sign that ovulation may be about to take place,[55] but it does not mean ovulation will definitely occur.[15]

Secretory phase

[edit]

The secretory phase is the final phase of the uterine cycle and it corresponds to the luteal phase of the ovarian cycle. During the secretory phase, the corpus luteum produces progesterone, which plays a vital role in making the endometrium receptive to the implantation of a blastocyst (a fertilized egg, which has begun to grow).[56] Glycogen, lipids, and proteins are secreted into the uterus[57] and the cervical mucus thickens.[58] In early pregnancy, progesterone also increases blood flow and reduces the contractility of the smooth muscle in the uterus[22] and raises basal body temperature.[59]

If pregnancy does not occur the ovarian and uterine cycles start over again.[47]

Anovulatory cycles and short luteal phases

[edit]
Main article: Anovulation

Only two-thirds of overtly normal menstrual cycles are ovulatory, that is, cycles in which ovulation occurs.[15] The other third lack ovulation or have a short luteal phase (less than ten days[60]) in which progesterone production is insufficient for normal physiology and fertility.[61] Cycles in which ovulation does not occur (anovulation) are common in girls who have just begun menstruating and in women around menopause. During the first two years following menarche, ovulation is absent in around half of cycles. Five years after menarche, ovulation occurs in around 75% of cycles and this reaches 80% in the following years.[62] Anovulatory cycles are often overtly identical to normally ovulatory cycles.[63] Any alteration to balance of hormones can lead to anovulation. Stress, anxiety and eating disorders can cause a fall in GnRH, and a disruption of the menstrual cycle. Chronic anovulation occurs in 6–15% of women during their reproductive years. Around menopause, hormone feedback dysregulation leads to anovulatory cycles. Although anovulation is not considered a disease, it can be a sign of an underlying condition such as polycystic ovary syndrome.[64] Anovulatory cycles or short luteal phases are normal when women are under stress or athletes increasing the intensity of training. These changes are reversible as the stressors decrease or, in the case of the athlete, as she adapts to the training.[60]

Menstrual health

[edit]
A human primary ovarian follicle viewed by microscopy. The round oocyte stained red in the center is surrounded by a layer of granulosa cells, which are enveloped by the basement membrane and theca cells. The magnification is around 1000 times. (H&E stain)

Although a normal and natural process,[65] some women experience premenstrual syndrome with symptoms that may include acne, tender breasts, and tiredness.[66] More severe symptoms that affect daily living are classed as premenstrual dysphoric disorder and are experienced by 3 to 8% of women.[4][67][66][68] Dysmenorrhea (menstrual cramps or period pain) is felt as painful cramps in the abdomen that can spread to the back and upper thighs during the first few days of menstruation.[69][70][71] Debilitating period pain is not normal and can be a sign of something severe such as endometriosis.[72] These issues can significantly affect a woman's health and quality of life and timely interventions can improve the lives of these women.[73]

There are common culturally communicated misbeliefs that the menstrual cycle affects women's moods, causes depression or irritability, or that menstruation is a painful, shameful or unclean experience. Often a woman's normal mood variation is falsely attributed to the menstrual cycle. Much of the research is weak, but there appears to be a very small increase in mood fluctuations during the luteal and menstrual phases, and a corresponding decrease during the rest of the cycle.[74] Changing levels of estrogen and progesterone across the menstrual cycle exert systemic effects on aspects of physiology including the brain, metabolism, and musculoskeletal system. The result can be subtle physiological and observable changes to women's athletic performance including strength, aerobic, and anaerobic performance.[75]

Changes to the brain have also been observed throughout the menstrual cycle[76] but do not translate into measurable changes in intellectual achievement – including academic performance, problem-solving, and memory.[77] Improvements in spatial reasoning ability during the menstruation phase of the cycle are probably caused by decreases in levels of estrogen and progesterone.[74]

In some women, ovulation features a characteristic pain[d] called mittelschmerz (a German term meaning middle pain). The cause of the pain is associated with the ruptured follicle, causing a small amount of blood loss.[20]

Even when normal, the changes in hormone levels during the menstrual cycle can increase the incidence of disorders such as autoimmune diseases,[81] which might be caused by estrogen enhancement of the immune system.[4]

Around 40% of women with epilepsy find that their seizures occur more frequently at certain phases of their menstrual cycle. This catamenial epilepsy may be due to a drop in progesterone if it occurs during the luteal phase or around menstruation, or a surge in estrogen if it occurs at ovulation. Women who have regular periods can take medication just before and during menstruation. Options include progesterone supplements, increasing the dose of their regular anticonvulsant drug, or temporarily adding an anticonvulsant such as clobazam or acetazolamide. If this is ineffective, or when a woman's menstrual cycle is irregular, then treatment is to stop the menstrual cycle occurring. This may be achieved using medroxyprogesterone, triptorelin or goserelin, or by sustained use of oral contraceptives.[82][83]

Hormonal contraception

[edit]
Main article: Hormonal contraception

Hormonal contraceptives prevent pregnancy by inhibiting the secretion of the hormones, FSH, LH and GnRH. Hormonal contraception that contains estrogen, such as combined oral contraceptive pills (COCPs), stop the development of the dominant follicle and the mid-cycle LH surge and thus ovulation.[84] Sequential dosing and discontinuation of the COCP can mimic the uterine cycle and produce bleeding that resembles a period. In some cases, this bleeding is lighter.[85]

Progestin-only methods of hormonal contraception do not always prevent ovulation but instead work by stopping the cervical mucus from becoming sperm-friendly. Hormonal contraception is available in a variety of forms such as pills, patches, skin implants and hormonal intrauterine devices (IUDs).[86]

Evolution and other species

[edit]
Further information: Menstruation (mammal)

Most female mammals have an estrous cycle, but only ten primate species, four bat species, the elephant shrews and the Cairo spiny mouse (Acomys cahirinus) have a menstrual cycle.[87][88] The cycles are the same as in humans apart from the length, which ranges from 9 to 37 days.[89][87] The lack of immediate relationship between these groups suggests that four distinct evolutionary events have caused menstruation to arise.[90] There are four theories on the evolutionary significance of menstruation:[90]

  1. Control of sperm-borne pathogens.[91][92][93] This hypothesis held that menstruation protected the uterus against pathogens introduced by sperm. Hypothesis 1 does not take into account that copulation can take place weeks before menstruation and that potentially infectious semen is not controlled by menstruation in other species.[90]
  2. Energy conservation.[92][94] This hypothesis claimed that it took less energy to rebuild a uterine lining than to maintain it if pregnancy did not occur. Hypothesis 2 does not explain other species that also do not maintain a uterine lining but do not menstruate.[90]
  3. A theory based on spontaneous decidualization (a process that results in significant changes to cells of the endometrium in preparation for, and during, pregnancy). Decidualization leads to the differentiation of the endometrial stroma, which involves cells of the immune system,[89] the formation of a new blood supply, hormones and tissue differentiation. In non-menstruating mammals, decidualization is driven by the embryo, not the mother.[95] According to this theory, menstruation is an unintended consequence of the decidualization process and the body uses spontaneous decidualization to identify and reject defective embryos early on.[96] This process happens because the decidual cells of the stroma can recognize and respond to defects in a developing embryo by stopping the secretion of cytokines needed for the embryo to implant.[96]
  4. Uterine pre-conditioning.[97] This hypothesis claims that a monthly pre-conditioning of the uterus is needed in species, such as humans, that have deeply invasive (deep-rooted) placentas. In the process leading to the formation of a placenta, maternal tissues are invaded. This hypothesis holds that menstruation was not evolutionary, rather the result of a coincidental pre-conditioning of the uterus to protect uterine tissue from the deeply rooting placenta, in which a thicker endometrium develops.[97] Hypothesis 4 does not explain menstruation in non-primates.[90]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Menstrual cycle

View on Grokipedia
from Grokipedia
The menstrual cycle is a recurring physiological process in females of reproductive age, involving coordinated hormonal changes that regulate development, , and preparation of the uterine for potential , typically culminating in if implantation does not occur. This cycle, driven by interactions among the , gland, ovaries, and , averages 28 days in length but exhibits substantial variability, with normal cycles ranging from 21 to 35 days. Minor fluctuations of a few days, such as a period arriving 4 days late or 6 days early, are common within this range and often result from factors such as stress, hormonal changes, illness, travel, weight fluctuations, intense exercise, or pregnancy (if sexually active). It encompasses the ovarian cycle, consisting of the (follicle maturation under [FSH] influence), (egg release triggered by a [LH] surge), and (corpus luteum formation producing progesterone), alongside corresponding uterine phases: menstrual (shedding of the ), proliferative (endometrial growth stimulated by ), and secretory (progesterone-induced glandular development). (GnRH) from the initiates the cascade, prompting pituitary secretion of FSH and LH, which in turn stimulate ovarian production of and progesterone to modulate cycle progression and feedback regulation. Disruptions in this hormonally orchestrated sequence can lead to irregularities such as amenorrhea or , though the cycle's core function remains the periodic readiness for , with empirical evidence underscoring its sensitivity to factors like age, stress, and .

Definition and Characteristics

Biological Definition and Purpose

The menstrual cycle refers to the approximately monthly series of physiological changes in the , characterized by cyclic alterations in the ovaries and driven by hormonal interactions among the , , ovaries, and . These changes culminate in , the release of a mature ovum from an , typically midway through the cycle. In the absence of fertilization, the process concludes with , the shedding of the endometrial lining. This cycle begins at , usually between ages 10 and 16, and continues until , averaging around age 51. Biologically, the purpose of the menstrual cycle is to prepare the female body for potential by coordinating maturation, ovum release, and uterine receptivity for implantation. Follicle development and enable the production of a fertilizable , while estrogen-driven endometrial proliferation creates a nutrient-rich environment to support early embryonic growth if conception occurs. If implantation fails, progesterone withdrawal triggers endometrial breakdown and , resetting the cycle for subsequent attempts. This mechanism ensures periodic fertility windows, optimizing reproductive success in species with , such as humans. Unlike continuous in males, the cyclic nature reflects an energy-efficient strategy for , limiting it to viable reproductive periods.

Typical Duration, Variability, and Markers

The typical menstrual cycle is measured from the first day of menstrual bleeding to the first day of the subsequent bleeding, with a length of 28 days observed in large cohorts of reproductive-age women. Most cycles range from 25 to 30 days, though a broader normal range extends from 21 to 35 days, encompassing 95% of cycles in healthy individuals without underlying . The duration of menstrual bleeding itself averages 5.8 days, with 95% of cycles featuring bleeding from 3 to 8 days, though clinical norms often specify 3 to 7 days as typical. Cycle length exhibits both between-woman and within-woman variability, with the latter typically not exceeding 7 to 9 days in ovulatory cycles for most women in their peak reproductive years. Variability is lowest between ages 35 and 39, increasing by approximately 45% to 46% in women aged 18 to 24 or over 40, reflecting physiological changes such as irregular in and perimenopause. Factors influencing variability include age, (BMI), stress, and exercise, while and alcohol consumption show no consistent impact in population studies. For instance, cycles lengthen by an average of 1.6 days in Asian women and 0.7 days in women compared to women, independent of age and BMI. Key markers delineate cycle progression: Day 1 signifies the onset of noticeable bright red menstrual bleeding (excluding light spotting or brown discharge), triggered by progesterone withdrawal; , confirmed by (LH) surge, typically occurs around day 14 in 28-day cycles but varies with length (averaging 15 days), while the remains more consistent at 12 to 14 days. For example, in a typical 28-day cycle with ovulation around day 14, day 18 is 4 days after ovulation (day 15 is 1 day after, day 16 is 2 days after, day 17 is 3 days after, and day 18 is 4 days after), placing it in the early luteal phase. The ovulatory window spans approximately 6 days, encompassing the 5 days prior to and the day of, as viability allows fertilization post-insemination. These markers rely on empirical tracking via shifts, cervical mucus changes, or urinary LH detection, with cycle irregularity (e.g., lengths outside 21-36 days) signaling potential or health disruptions in fewer than 3% of tracked cycles among app users.

Hormonal Regulation

Key Hormones Involved

The menstrual cycle is primarily regulated by interactions within the hypothalamic-pituitary-ovarian (HPO) axis, involving (GnRH), (FSH), (LH), (the primary ), and progesterone. GnRH is secreted in a pulsatile manner by neurons in the , with pulse frequency and amplitude varying across the cycle to modulate release. This ensures tonic stimulation of the gland, preventing desensitization and maintaining reproductive function. FSH and LH, both glycoprotein gonadotropins produced by the , drive ovarian and steroidogenesis. FSH primarily stimulates the growth and maturation of ovarian follicles during the , promoting proliferation and the expression of enzyme, which converts to estrogens. LH complements FSH by inducing cell production and, in a mid-cycle surge, triggers by causing follicular rupture and luteinization of into the . The LH/FSH ratio shifts dynamically, with higher FSH early in the cycle favoring follicle recruitment and increasing LH later to support . Estradiol, synthesized mainly in granulosa cells under FSH influence, exerts on the HPO axis at low levels to suppress FSH and maintain follicular selection, but rises to induce triggering the LH surge when thresholds are met. Progesterone, produced post-ovulation by the under LH stimulation, prepares the for implantation and exerts to inhibit GnRH, FSH, and LH, preventing further . If does not occur, declining progesterone levels signal luteolysis, restarting the cycle. Inhibin, secreted by granulosa cells, selectively suppresses FSH to refine follicle selection, while activin enhances FSH effects. These hormones collectively ensure synchronized ovarian and uterine changes, with disruptions in their balance underlying common reproductive disorders.

Feedback Mechanisms and Axis Dynamics

The hypothalamic-pituitary-ovarian (HPO) axis orchestrates the menstrual cycle through pulsatile (GnRH) secretion from the , which stimulates the to release (FSH) and (LH), thereby driving development and steroidogenesis. GnRH is released in pulses from the arcuate nucleus, with pulse frequency modulating the FSH-to-LH ratio: higher frequencies favor LH secretion, while slower frequencies promote FSH dominance, influencing phase-specific ovarian responses. Ovarian products, including (E₂), progesterone, and inhibins, exert feedback on the axis to maintain cyclicity. Negative feedback predominates to regulate gonadotropin levels and prevent overstimulation. In the follicular phase, rising E₂ and inhibin B from granulosa cells suppress FSH secretion at the pituitary, selectively allowing the dominant follicle (typically 18-29 mm in diameter) to persist while atresia occurs in others; low progesterone levels contribute minimally at this stage. During the luteal phase, elevated E₂, progesterone, and inhibin A further inhibit both FSH and LH, reducing GnRH pulse frequency (to intervals exceeding 200 minutes) via opioid-mediated pathways, which sustains the corpus luteum until luteolysis. This feedback ensures intercycle homeostasis, with declining luteal steroids permitting an FSH rise to initiate the next follicular phase. Positive feedback occurs transiently in the late to trigger . Sustained high E₂ levels (for at least 34-48 hours) from the preovulatory follicle sensitize the pituitary to GnRH, inducing a surge in LH (10-fold increase) and, to a lesser extent, FSH, typically around day 14 of a 28-day cycle; follows 36-44 hours later. This mechanism overrides temporarily, modulated by non-steroidal factors like surge-attenuating factor (GnSAF), which limits surge amplitude to prevent hyperstimulation. Disruptions in these loops, such as altered GnRH pulsatility, can impair cyclicity, though normal dynamics rely on precise steroidal thresholds and ovarian-pituitary reciprocity.

Cycle Phases

Menstrual Phase

The menstrual phase (Persian: مرحله قاعدگی or فاز قاعدگی; days 1–5) constitutes the initial segment of the menstrual cycle, commencing on the first day of noticeable bright red vaginal bleeding (not including premenstrual spotting or brown discharge) and involving the shedding of the endometrium's functional layer. This process is precipitated by the regression of the in the preceding , resulting in a precipitous decline in progesterone and concentrations. The withdrawal of these steroid hormones destabilizes the endometrial vasculature, leading to ischemia, , and subsequent expulsion of the superficial endometrial tissue through menstrual . Typically, the menstrual phase endures for 3 to 7 days, with bleeding volume ranging from 20 to 90 milliliters across the period. The heaviest flow occurs in the initial 1 to 2 days, diminishing thereafter as ensues and endometrial repair initiates. Prostaglandins, synthesized by the in response to hormonal withdrawal, mediate that facilitate expulsion of debris and contribute to associated in susceptible individuals. Physiologically, the process encompasses localized inflammation and enzymatic degradation of the within the , enabling orderly shedding without deep tissue invasion under normal conditions. (FSH) levels begin to rise modestly toward the phase's conclusion, stimulating ovarian follicular recruitment for the ensuing . Variability in duration and flow can occur due to factors such as age, with adolescents often experiencing longer or irregular bleeding patterns. Excessive or prolonged bleeding exceeding 80 milliliters or 7 days warrants clinical evaluation to exclude pathologies like coagulopathies or structural abnormalities.

Follicular Phase

The follicular phase (Persian: مرحله فولیکولی or فاز فولیکولار; days 1–13) commences on the first day of menstrual bleeding and extends until , typically spanning days 1 to 14 in a standard 28-day cycle, though its length varies between 10 and 16 days across individuals due to differences in ovulation timing. This phase is characterized by the recruitment and maturation of s under the influence of (FSH), with one dominant follicle ultimately selected for while others undergo . Early in the phase, low levels of FSH from the stimulate the growth of multiple primordial follicles in the ovaries, transitioning them to primary and secondary stages with proliferation of granulosa and cells. As follicles develop, they produce increasing amounts of , which rises gradually from low levels post-menses, peaking just before to exert on FSH secretion, thereby suppressing further follicle recruitment and promoting selection of the dominant follicle. Luteinizing hormone (LH) remains low during most of this period but, in response to rising levels providing , surges mid-cycle to trigger . Concurrently, the proliferative phase occurs in the , where rising stimulates endometrial regeneration and thickening, with glandular proliferation and increased preparing the lining for potential implantation. Inhibin B, secreted by granulosa cells, further modulates FSH levels to fine-tune follicular development. Empirical measurements indicate levels increase from approximately 30-50 pg/mL early in the phase to over 200 pg/mL pre-ovulation, correlating with follicle diameters exceeding 10 mm for the dominant structure.

Ovulation

Ovulation (Persian: مرحله تخمک‌گذاری or فاز اوولاسیون; around day 14) is the physiological event in which a mature is released from the dominant into the and subsequently captured by the fimbriae of the . This process marks the midpoint of the menstrual cycle in fertile women, enabling potential fertilization. In a standard 28-day menstrual cycle, typically occurs around day 14, approximately 14 days prior to the onset of , though cycle length variability influences exact timing. Consequently, day 18 occurs 4 days after ovulation (with day 15 being 1 day after ovulation, day 16 two days after, day 17 three days after, and day 18 four days after), placing it in the early luteal phase. The event is triggered by a preovulatory surge in (LH) secreted by the gland, stimulated by rising levels from the maturing follicle exerting on the hypothalamic-pituitary axis. The LH surge duration averages 24 to 48 hours, with ensuing 24 to 36 hours after its onset or 10 to 12 hours following the LH peak. The LH surge induces enzymatic degradation of the follicular wall, leading to rupture of the graafian follicle and expulsion of the surrounded by cumulus cells. The released remains viable for fertilization for about 12 to 24 hours, while spermatozoa can survive in the female reproductive tract for up to 5 days, defining the fertile window. Post-ovulation, the ruptured follicle transforms into the , which secretes progesterone to support potential implantation. Detection of ovulation relies on methods such as urinary LH kits, which identify the surge with high sensitivity; monitoring, showing a post-ovulatory rise of 0.5 to 1°F due to progesterone; and transvaginal visualizing follicular collapse. Some women symptoms like , a mid-cycle lower from follicular rupture, occurring in up to 20% of cycles, alongside changes in cervical mucus to a clear, stretchy consistency favoring transport. Empirical validation confirms these biomarkers correlate with -confirmed ovulation, though individual variability necessitates combined methods for accuracy.

Luteal Phase

The luteal phase (Persian: مرحله لوتئالی or فاز لوتئال; days 15–28) begins immediately after , when the ruptured graafian follicle transforms into the , a temporary in the . In a typical 28-day menstrual cycle, ovulation occurs around day 14, so day 18 is 4 days after ovulation and thus occurs in the early luteal phase. This structure primarily secretes progesterone, with lesser amounts of and inhibin A, to support endometrial preparation for potential implantation. Progesterone production depends on (LH) stimulation and availability, peaking in the mid-luteal period to induce secretory transformation of the endometrium, including glandular proliferation and vascular changes essential for nutrient provision to an . The phase typically spans 12 to 14 days, from to the onset of menses, showing lower inter- and intra-woman variability compared to the , with a duration of 14 days and a normal range of 11 to 17 days. This relative constancy arises from the corpus luteum's finite lifespan, regulated by LH pulses; in the absence of fertilization, LH secretion declines, leading to luteal regression around day 10 to 12 post-. Progesterone levels rise sharply post-, reaching maxima of 10-20 ng/mL mid-phase before declining if no occurs, which destabilizes the and initiates via prostaglandin-mediated . elevates by 0.3-0.5°C due to progesterone's thermogenic effects, serving as a clinical marker. In the event of fertilization, (hCG) from the developing embryo sustains the , prolonging progesterone secretion into early until the assumes production around weeks 8-10. Endometrial shifts to a decidualized state under progesterone influence, with stromal cells enlarging and spiral arteries coiling to facilitate implantation. Empirical data from cycle tracking confirm progesterone's causal role in suppressing uterine contractility and enhancing at the maternal-fetal interface. Short luteal phases under 10 days, observed in 5-10% of cycles, correlate with reduced due to inadequate progesterone exposure, often linked to factors like stress or dysfunction disrupting LH support.

Irregularities and Disorders

Menstrual irregularities encompass deviations from typical cycle patterns, including alterations in cycle length, bleeding characteristics, and ovulatory function. Cycles typically range from 21 to 35 days, with occasional variations of a few days being common and often attributable to transient factors such as stress, hormonal fluctuations, weight changes, intense physical activity, illness, travel, or certain medications. An isolated early period (e.g., several days early) is frequently within normal limits. Similarly, an isolated late period (e.g., 4 days late) is often normal and not a cause for concern, as menstrual cycles naturally vary, commonly due to the same transient factors, changes in diet or exercise, or pregnancy (if sexually active). However, persistent short cycles (consistently fewer than 21 days) or persistent long cycles (consistently more than 35 days) may indicate underlying disorders such as thyroid dysfunction, polycystic ovary syndrome (PCOS), endometriosis, or other hormonal imbalances, and merit medical evaluation, particularly when accompanied by additional symptoms like severe dysmenorrhea, heavy bleeding, intermenstrual spotting, unusual weight changes, fatigue, or possible pregnancy.

Anovulatory Cycles

Anovulatory cycles occur when fails to take place during a menstrual cycle, resulting in the absence of release from the ovarian follicles despite potential endometrial shedding and . In such cycles, production continues from developing follicles, leading to endometrial proliferation without the subsequent progesterone surge from a , which can cause irregular or heavy withdrawal upon estrogen decline. This distinguishes anovulatory from ovulatory patterns, where progesterone stabilizes the endometrium before orderly shedding. Prevalence varies by age and population; nearly all reproductive-age women experience sporadic anovulatory cycles, with rates reaching approximately 37% in studies of women reporting normal-length cycles (21-35 days). In adolescents, anovulation is particularly common, affecting about 50% of cycles in the first two years post-menarche due to hypothalamic-pituitary-ovarian axis immaturity, though many such cycles still fall within 21-45 days. Chronic anovulation underlies up to 30% of cases, often linked to underlying disorders like . Frequency decreases with age until perimenopause, where anovulatory cycles again rise due to declining . Common causes include disruptions in pulsatility from stress, excessive exercise, or nutritional deficits; hyperandrogenic states such as PCOS; dysfunction; or hyperprolactinemia. In adolescents, transient immaturity of the reproductive axis predominates, while in adults, or rapid weight loss can elevate via in , perpetuating unopposed stimulation. Premature ovarian insufficiency or perimenopausal also contributes by limiting mature development. Clinically, anovulatory cycles may present with oligomenorrhea, amenorrhea, or dysfunctional uterine bleeding characterized by prolonged or heavy flows, though some mimic eumenorrheic patterns without overt irregularity. Associated symptoms can include milder premenstrual complaints due to absent luteal progesterone, but chronic cases risk from sustained exposure, elevating hyperplasia and odds by 2-4 fold if untreated beyond two years. arises directly from lack of gamete release, with no fertile window. Diagnosis relies on menstrual history revealing irregular patterns, confirmed by mid-luteal progesterone levels below 3-5 ng/mL (indicating no ), serial ultrasounds showing absent dominant follicle collapse or , or lacking a sustained rise. Further evaluation excludes structural or endocrine pathologies via , assays, and pelvic imaging. Management targets underlying etiologies; lifestyle modifications like weight normalization restore ovulatory function in 30-50% of obesity- or exercise-related cases. Pharmacologic induction employs clomiphene citrate or to stimulate follicle development, achieving ovulation in 60-80% of cycles for treatment. For bleeding control or endometrial protection, progestins or combined oral contraceptives impose cyclic withdrawal, though these suppress natural . In resistant cases, gonadotropins or assisted reproduction may be required, with success rates varying by age and cause.

Short Luteal Phases

A short luteal phase is defined as a duration of 10 days or fewer from to the onset of , contrasting with the typical 12-14 days observed in most ovulatory cycles. This condition, often termed luteal phase deficiency (LPD) when accompanied by suboptimal progesterone levels or endometrial development, arises from inadequate function, resulting in insufficient progesterone secretion to sustain the uterine lining. Physiologically, the forms post- from the ruptured follicle and peaks progesterone output around days 6-8 of the luteal phase; premature regression leads to an early drop in progesterone, triggering endometrial breakdown and menses. Prevalence data indicate short s occur in approximately 8-13% of ovulatory cycles among regularly menstruating women, though recurrent episodes affect only about 3% of cycles in prospective studies. In one analysis of over 700 cycles, 55% of women experienced at least one short luteal phase (<10 days), often linked to subtle hormonal imbalances rather than overt pathology. Empirical evidence from cohort studies shows women with short luteal lengths in initial cycles exhibit reduced fecundity, with fertility rates dropping significantly after six months of attempting conception compared to those with normal phases. Causal factors include impaired folliculogenesis leading to a suboptimal luteinizing hormone (LH) surge, which compromises corpus luteum formation and progesterone output; additional contributors encompass hyperprolactinemia, thyroid dysfunction, and elevated stress-induced cortisol, all disrupting gonadotropin-releasing hormone pulsatility. Conditions like polycystic ovary syndrome (PCOS) exacerbate risk through irregular ovulation, while excessive exercise or low body weight can shorten phases via hypothalamic suppression. Unlike anovulatory cycles, short luteal phases involve confirmed ovulation but deficient post-ovulatory support, potentially causing early implantation failure or subclinical pregnancy loss due to inadequate secretory transformation of the endometrium. Diagnosis relies on prospective cycle tracking via basal body temperature (BBT) charting, urinary LH kits, or serial progesterone assays (e.g., mid-luteal levels <10 ng/mL indicating deficiency), though endometrial biopsy—once standard—lacks reliability and is discouraged. Symptoms may include intermenstrual spotting, abbreviated cycles (<25 days total), or a sluggish BBT rise, but these overlap with normal variation, complicating attribution. Regarding fertility impacts, while short phases correlate with delayed conception in observational data, randomized trials show no consistent benefit from progesterone supplementation in unselected infertile couples, prompting guidelines to reserve treatment for documented recurrent miscarriage or assisted reproduction cycles. This reflects causal uncertainty, as short phases in isolation do not invariably impair outcomes and may represent a marker of underlying ovulatory inefficiency rather than a primary defect.

Associated Conditions like PCOS and Endometriosis

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by ovulatory dysfunction, hyperandrogenism, and often polycystic ovarian morphology, leading to disrupted menstrual cyclicity in the majority of affected individuals. It impacts 6-13% of women of reproductive age globally, with up to 70% of cases remaining undiagnosed due to variable presentation and diagnostic challenges. In PCOS, elevated luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH), combined with insulin resistance and hyperandrogenism, impairs follicular development and ovulation, resulting in anovulatory cycles manifested as oligomenorrhea (cycles >35 days) or amenorrhea (fewer than 8 periods per year). Approximately 85-90% of women with PCOS experience oligo-ovulation, prolonging intervals between bleeds and increasing unopposed estrogen exposure, which elevates risks for endometrial hyperplasia. Causal factors include genetic predispositions and metabolic influences, though etiology remains multifactorial without a single definitive mechanism. Endometriosis involves the ectopic growth of endometrial-like tissue outside the , affecting approximately 10% of women of reproductive age worldwide and contributing to and in up to 50% of cases. It is linked to menstrual irregularities such as (menorrhagia) and , with evidence indicating that shorter cycle lengths (<27 days) and heavier flow increase disease risk, potentially via enhanced retrograde menstruation where menstrual effluent refluxes through fallopian tubes, seeding peritoneal implants. These implants respond to ovarian hormones, exacerbating inflammation and adhesions that can distort pelvic anatomy, indirectly disrupting ovulatory timing and cycle regularity through altered feedback on the hypothalamic-pituitary-ovarian axis. While retrograde menstruation is a supported theory, immune dysregulation and genetic factors also contribute, with no consensus on primary causation. Both conditions intersect with menstrual cycle dynamics: PCOS primarily via anovulation and androgen excess halting follicular progression, and endometriosis through inflammatory interference with endometrial shedding and hormonal signaling. Co-occurrence is noted in clinical populations, with shared risks like nulliparity amplifying infertility burdens, though distinct pathogeneses underscore the need for targeted diagnostics such as transvaginal ultrasound for PCOS polycysts or laparoscopy for endometriosis confirmation. Empirical data from cohort studies emphasize early screening using cycle history as a vital sign, as prolonged irregularities predict metabolic comorbidities in PCOS and progression in endometriosis.

Physiological Impacts and Health

Symptoms, PMS, and Empirical Effects

The menstrual cycle is associated with a range of physical and psychological symptoms that vary in prevalence and intensity across phases, with somatic symptoms such as abdominal cramps and breast tenderness reported in over 80% of cycles in large cohorts. Mood changes and anxiety affect approximately 90.6% of women, while fatigue impacts 86.2%, often peaking in the luteal phase due to progesterone fluctuations. These symptoms are empirically linked to ovarian hormone dynamics, with prospective studies confirming their cyclical nature rather than random occurrence. Premenstrual syndrome (PMS) manifests as a cluster of symptoms in the late , resolving shortly after menstruation onset, affecting 12% of women by strict diagnostic criteria and up to 4% severely. Core symptoms include irritability (85%), anxiety (83%), and mood lability (77%), alongside physical manifestations like fatigue (88.7%) and bloating. Empirical data from prospective tracking refute retrospective recall biases, showing symptom stability across cycles and higher reliability when confirmed daily rather than self-reported historically. Prevalence varies by population, with somatic symptoms predominating over affective ones in most studies, challenging narratives emphasizing emotional disruption as primary. Nutrient considerations contribute to symptom management; iron losses during the menstrual phase necessitate elevated replenishment to prevent deficiency, with needs highest post-menstruation. In the luteal phase, serum magnesium and calcium levels often decline, and supplementation with magnesium, calcium, vitamin D, and B vitamins—particularly B6—alleviates PMS symptoms including cramps, mood changes, bloating, and fluid retention through support for hormone balance, mood regulation, and calcium absorption. Empirical investigations reveal cycle-phase-specific effects, with negative mood and psychiatric symptoms—including depression, anxiety, and suicidality—elevating in the perimenstrual window (late luteal to early follicular), corroborated by meta-analyses of clinical cohorts. Physical pain prevalence reaches 66.8%, with 13.3% reporting severe dysmenorrhea tied to prostaglandin-mediated uterine contractions. These effects are modulated by hormone levels, as estradiol-progesterone ratios influence serotonin and GABA pathways, yielding measurable impacts on daily functioning without universal impairment. Severe variants like premenstrual dysphoric disorder (PMDD) occur in 1.6% globally, distinct from PMS by marked functional decline, supported by blinded symptom charting over multiple cycles.

Neurological and Cognitive Influences

Fluctuations in estradiol and progesterone levels across the menstrual cycle modulate brain structure and function through mechanisms including synaptogenesis, , and alterations in spine density. Neuroimaging research reveals phase-dependent changes in whole-brain dynamics, with increased functional connectivity in networks associated with executive control during the luteal phase, potentially driven by progesterone's influence on medial temporal lobe volume. These effects extend to neurotransmitter modulation, where estrogen enhances serotonin and dopamine signaling, while progesterone interacts with GABA receptors, contributing to neuroprotective processes and stress response regulation via hippocampal pathways. A 2025 meta-analysis synthesizing data from 134 studies involving over 7,000 participants found no reliable evidence of menstrual cycle phase influencing cognitive domains such as verbal fluency, spatial rotation, memory, attention, or executive function, with effect sizes near zero after correcting for publication bias and methodological confounders like small sample sizes. This challenges earlier hypotheses of ovulation-related enhancements in verbal tasks or luteal impairments in spatial cognition, which often failed replication due to variability in hormone assays and testing timing. Limited inconsistencies persist in specific contexts, such as marginally better pre-ovulatory performance on attention tasks in some cohorts, but these do not generalize across populations. Hormonal influences on emotion processing show more consistent phase effects, with enhanced recognition of emotional stimuli and fear extinction during high-estrogen follicular phases, linked to amygdala and prefrontal cortex activation patterns. Progesterone's role in these processes may underlie subtle connectivity shifts in limbic regions, though direct cognitive translation remains minimal. Overall, while neurological adaptations are evident, they yield negligible impacts on measurable cognitive performance in healthy individuals.

Cycle as a Vital Sign for Health Monitoring

The menstrual cycle functions as a vital sign reflecting the coordinated activity of the reproductive endocrine system and broader physiological health, akin to temperature or pulse in signaling disruptions. Regular cycles, defined as occurring every 21 to 35 days with predictable ovulation and menstruation, indicate balanced hypothalamic-pituitary-ovarian function and adequate energy availability for reproduction. Deviations in length, frequency, or symptoms—such as cycles shorter than 21 days (polymenorrhea) or longer than 35 days (oligomenorrhea)—often arise from underlying factors including insulin resistance, adrenal disorders, or chronic inflammation, rather than isolated gynecological issues. Prospective cohort studies demonstrate that persistent irregularity correlates with elevated risks for systemic conditions; for example, women reporting irregular cycles in adolescence and adulthood face a 1.5- to 2-fold higher likelihood of developing type 2 diabetes, hypertension, and dyslipidemia, independent of body mass index. These associations stem from shared causal pathways, such as impaired ovarian steroidogenesis mirroring metabolic dysregulation, with evidence from the Nurses' Health Study II showing irregular cycles predicting a 20-30% increased hazard ratio for cardiovascular disease events over 20 years of follow-up. , particularly functional hypothalamic amenorrhea from low energy states like excessive athletic training or undernutrition, signals risks for bone density loss and infertility, with recovery tied to restoring caloric balance. Tracking parameters like cycle length variability (standard deviation >5 days indicating irregularity), bleeding volume (assessed via pictorial blood loss charts), and mid-cycle symptoms enables early identification of endocrine disruptions. For instance, shortened luteal phases (<10 days) detected through or urinary metabolites may precede overt or elevations, prompting targeted screening. Longitudinal data from over 79,000 participants in the Apple Women's Health Study confirm that self-reported cycle data predict conditions like PCOS with high sensitivity, underscoring monitoring's role in preventive care without relying on invasive diagnostics. While apps and wearables facilitate this, validation against hormonal assays reveals their utility diminishes with high variability, emphasizing clinician integration for accuracy. In , incorporating cycle history into routine assessments—starting at —has been advocated to detect non-reproductive morbidities; a 2023 analysis linked early irregular patterns to a 15% higher all-cause mortality risk in midlife, attributable to compounded cardiometabolic and ovulatory deficits. This approach prioritizes empirical tracking over symptom dismissal, as causal evidence from intervention trials shows cycle normalization via or medical correction reduces associated comorbidities.

Interventions and Management

Hormonal Contraception: Mechanisms and Consequences

Hormonal contraceptives, primarily combined oral contraceptives containing synthetic and progestins, exert their effects through multiple mechanisms that disrupt the natural menstrual cycle. The primary action involves on the hypothalamic-pituitary-ovarian axis, suppressing (GnRH) pulsatility, which inhibits the (LH) surge necessary for . This follicular suppression prevents dominant follicle development and estrogen surges, effectively halting cyclic ovarian activity in most users. Progestins further contribute by thickening cervical mucus to impede sperm transport and by inducing endometrial , rendering the lining thin and unreceptive to implantation. in combined formulations stabilize the endometrium during active pill phases but promote withdrawal bleeding upon hormone withdrawal, mimicking menses without true ovulatory cycling. These interventions profoundly alter menstrual patterns, often replacing spontaneous cycles with predictable but artificial withdrawal bleeds. Users typically experience reduced cycle variability and lighter volumes due to endometrial thinning, though or unscheduled bleeding occurs in up to 20-30% during initial months from inconsistent suppression. Long-term use suppresses endogenous hormone fluctuations, including progesterone and peaks, leading to amenorrhea in continuous regimens or progestin-only methods. Upon discontinuation, ovulatory cycles generally resume within 1-3 months for most women, though delayed return can occur in 5-10% of cases, particularly with depot formulations. Health consequences extend beyond contraception, with empirical data revealing both protective and adverse effects tied to cycle suppression. Reduced ovulatory events correlate with lowered risks of (by 30-50% after 5+ years of use) and (by 50% or more), attributed to fewer lifetime exposures to unopposed . Conversely, a modest increase in risk ( 1.2-1.3 during use) has been observed in meta-analyses, potentially resolving post-discontinuation, though high-quality evidence for remains limited. density may decline in adolescents using low- or ultra-low-dose formulations, with reductions up to 1-2% annually due to suppressed peaks critical for peak bone accrual, raising concerns for long-term risk. Neurological and psychological impacts arise from altered profiles, with some longitudinal studies linking use to elevated depression symptoms ( 1.8 in adolescents) and anxiety, possibly via disrupted ovarian signaling in brain regions like the . Systematic reviews indicate inconsistent associations with mood disorders overall, but analyses highlight higher risks in women with prior vulnerabilities or during initiation. Other cycle-related consequences include potential masking of underlying disorders like PCOS, as suppressed obscures diagnostic patterns, and increased markers that may compound cardiovascular risks over decades of use. While protective against certain gynecologic conditions, these interventions' net effects underscore trade-offs, with benefits most evident in short-term use and risks accruing cumulatively.

Natural Tracking Methods and Fertility Awareness

Fertility awareness methods (FAMs), also termed , rely on daily observation of endogenous biomarkers to delineate the fertile window within the menstrual cycle, enabling informed decisions for contraception or conception without exogenous hormones or devices. These biomarkers include (BBT), cervical mucus characteristics, and menstrual cycle length patterns, which reflect underlying hormonal dynamics driven by and progesterone fluctuations. Accurate determination of the menstrual cycle start, defined as Day 1 being the first day of bright red menstrual bleeding (excluding spotting or brown discharge), is essential for reliable cycle length tracking. Proper application requires consistent charting and interpretation, often facilitated by trained instruction to minimize errors in identifying the approximately five-to-six-day fertile period encompassing . Basal body temperature tracking involves measuring oral temperature immediately upon waking using a sensitive to 0.01°C increments, revealing a biphasic : temperatures 36.1–36.4°C (97–97.5°F) pre-ovulation, rising 0.22–0.5°C (0.4–0.9°F) post-ovulation due to progesterone's thermogenic effect on the , with the shift sustained for 10–16 days until menses or . This method confirms retrospectively but cannot predict it prospectively, as the rise occurs 12–36 hours after the luteinizing hormone surge, limiting its standalone use for avoiding intercourse during peak . A sustained elevation beyond 18 days may indicate early via progesterone maintenance. Cervical mucus monitoring assesses daily, noting sensation (dry/sticky versus wet/slippery) and appearance (cloudy versus clear and stretchable like raw ), which correlates with peaks promoting and survival up to five days pre-. Fertile , peaking 1–2 days before , transitions from scant and opaque in the infertile pre-ovulatory phase to abundant, elastic, and lubricative, then diminishes post- under progesterone influence, signaling . External factors like fluid, , or infections can confound observations, necessitating protocols and experience for accurate discernment. The symptothermal method integrates BBT, cervical mucus, and optional cervical palpation (noting softening and opening near ovulation) for cross-verification, reducing false positives in fertile phase identification. Peer-reviewed evaluations of symptothermal protocols report perfect-use pregnancy avoidance rates of 95.9–99.6% (Pearl Index 0.4–4.1 per 100 woman-years), with typical-use rates of 76–88% influenced by adherence, cycle regularity, and user discipline. These figures outperform calendar-based methods alone, which assume fixed cycle lengths and yield typical effectiveness of 76–91% but falter with variability exceeding five days. Effectiveness hinges on avoiding unprotected intercourse or using barriers during the identified fertile window, typically days 8–19 in a 28-day cycle, and requires 3–6 months of baseline charting for personalization. Beyond contraception, FAMs enhance for conception by timing intercourse to the fertile peak or BBT rise onset, with studies showing reduced time-to-pregnancy in users versus non-trackers. They also serve as non-invasive tools for detecting or luteal defects through absent thermal shifts or shortened post-peak phases (<10 days), prompting medical evaluation without synthetic interventions. Limitations include unsuitability for irregular cycles (e.g., postpartum, perimenopausal, or stress-induced), higher discontinuation rates due to regimen demands (up to 47% in some cohorts), and suboptimal in adolescents or those with infrequent coitus. Mobile applications purportedly automating FAMs via algorithms often lack rigorous validation, yielding variable accuracy compared to manual symptothermal charting. Structured training from certified instructors improves outcomes, as self-taught methods exhibit higher failure rates from misinterpretation.

Evolutionary and Comparative Biology

Evolutionary Theories and Reproductive Function

The menstrual cycle in humans, characterized by overt , represents an evolutionary divergence from the predominant mammalian pattern of endometrial without shedding. This difference has prompted hypotheses centered on adaptive advantages in , particularly in the context of invasive and embryo selection. Spontaneous —the preemptive transformation of the into a decidualized state prior to implantation—underpins the cycle's reproductive function, enabling rigorous screening of embryos for genetic compatibility and reducing risks from defective implantations. In non-menstruating mammals, decidualization typically requires an embryonic signal, but in humans and other menstruating , it occurs independently, leading to menstrual shedding if no viable implants; this mechanism likely evolved to accommodate hemochorial , where the deeply invades the uterine wall, necessitating a thickened, vascularized for nutrient exchange and immune modulation. One prominent theory posits as a byproduct of enhanced rather than a direct adaptation, with the cycle's phasing optimizing by aligning follicular development, , and luteal support for implantation windows that favor high-quality embryos. Empirical data from comparative indicate that menstruating species exhibit more advanced endometrial preparation, correlating with lower rates of ectopic pregnancies and early embryonic loss compared to reabsorbing species, though direct causation remains correlative. This framework emphasizes the cycle's role in maternal-fetal , where expels non-viable or paternally biased embryos, preserving maternal resources for future cycles; genetic assimilation models suggest this trait stabilized in hominid lineages around 30-40 million years ago, coinciding with diversification and increased maternal investment. Alternative hypotheses focus on menstruation's potential antipathogen function, proposing that cyclic shedding mechanically and chemically clears the of sperm-transmitted microbes, thereby protecting oviducts and supporting reproductive tract integrity for subsequent fertilizations. Margie Profet's 1993 model argues that menstrual flow exerts pressure to dislodge infected tissues, with supporting evidence from elevated in menstrual effluent and higher risks in amenorrheic states; however, critiques note that sexually transmitted diseases persist in menstruating women, and prevalence does not strictly predict menstrual intensity across . Beverly Strassmann's energy economy perspective counters claims of high metabolic cost, estimating that shedding is energetically cheaper than prolonged maintenance of a non-pregnant , based on longitudinal data from Dogon women showing lifetime blood loss equivalent to 7-10 liters despite frequent pregnancies and lactational suppression reducing cycle frequency to about 100 per lifetime. These theories converge on the cycle's ultimate reproductive function: maximizing in environments with variable opportunities and embryonic viability, as evidenced by cycle synchronization with peak (days 10-14) enhancing conception probabilities to 20-30% per ovulatory window in natural populations. Disruptions, such as short luteal phases, correlate with reduced implantation success, underscoring the cycle's evolved precision in orchestration— surges for follicle maturation and progesterone for endometrial receptivity—selected for in ancestral humans with to promote paternal investment via paternity uncertainty. While no single theory fully resolves the evolutionary puzzle, empirical metrics like interbirth intervals (3-4 years in hunter-gatherers) and lifetime (4-6 offspring) affirm the cycle's net adaptive value over non-cyclic alternatives.

Menstruation in Non-Human Species

Menstruation, defined as the cyclic shedding of the with overt , is observed in fewer than 2% of mammalian species and is predominantly confined to . Among non-human , it occurs in catarrhines, including monkeys such as macaques and baboons, as well as great apes like chimpanzees, , and orangutans. In these species, the process mirrors in involving progesterone-driven endometrial followed by sloughing if implantation does not occur, though cycle lengths vary; for instance, chimpanzees exhibit cycles averaging 35 days. (platyrrhines) generally lack overt , instead reabsorbing endometrial tissue during non-pregnant cycles, though limited evidence suggests subtle shedding in species like Poeppig's . Beyond primates, menstruation is documented in select non-primate mammals, including certain , the , and one species. At least three bat species exhibit menstruation, such as the short-tailed fruit bat (Carollia perspicillata), where bleeding is confined to a single day within a 33-day cycle observed in both wild and captive populations. The spiny mouse (Acomys cahirinus), identified in 2016 as the first naturally menstruating rodent, displays endometrial shedding with bleeding every 9-11 days, accompanied by spiral artery formation and inflammatory responses akin to . Elephant shrews (Elephantulus spp.) also show menstrual bleeding, though details on cycle physiology remain less studied compared to . In non-menstruating mammals, which comprise over 98% of species, the undergoes reabsorption or minimal, non-bleeding shedding during estrous cycles, minimizing energy loss from overt blood expulsion. This rarity underscores menstruation's evolutionary novelty, potentially linked to enhanced for protection in species with invasive , though causal mechanisms differ across taxa. Recent has induced menstruation in mice for purposes, but this does not reflect natural occurrence.

Myths, Misconceptions, and Debates

Prevalent Myths and Empirical Debunking

A persistent misconception holds that women living in close proximity, such as roommates or residents, experience menstrual cycle , a popularized by a 1971 study suggesting pheromonal influence. Subsequent rigorous analyses, including longitudinal tracking of over 800 cycles in college women, revealed no statistically significant convergence of onset dates beyond what random variation predicts, attributing apparent synchrony to methodological artifacts like retrospective and small sample sizes. A 2023 roommate study similarly found mean onset differences unchanged over time, confirming the effect as illusory. Another widespread belief is that the human menstrual cycle universally adheres to a 28-day length, often presented in educational materials as the standard. Empirical data from a exceeding 600,000 cycles across diverse populations indicate an average length of 29.3 days, with only 13% precisely at 28 days and a normal range spanning 21 to 35 days without . Cycle variability increases with age extremes, stress, and , underscoring that deviation from 28 days reflects biological norm rather than irregularity. A related misconception posits that menstrual cycles systematically skip the month of February each year due to its shorter duration. Menstrual cycles follow biological processes averaging 29.3 days, with normal variation of 21–35 days or more, driven by hormonal regulation, stress, health conditions, weight changes, and life stages rather than calendar structure. February's 28 or 29 days may coincidentally align with certain cycle lengths, potentially causing periods to appear to skip the month for some individuals (e.g., onset in late January followed by March), but this represents anecdotal coincidence, not a universal or annual pattern across populations. The notion that menstrual cycle phases induce cognitive deficits or irrationality in women, particularly premenstrually, persists in cultural narratives despite lacking empirical foundation. A 2025 meta-analysis synthesizing 106 studies and over 4,000 participants detected no reliable phase-related alterations in domains including verbal fluency, spatial reasoning, , , or executive function, with effect sizes near zero after correcting for . While self-reported mood fluctuations occur in 20-30% of cycles for some women, these do not translate to measurable impairments in or performance, challenging stereotypes of diminished capacity. Claims that (PMS) represents mere psychological exaggeration or fabrication ignore physiological evidence, yet the inverse myth—that PMS invariably causes profound behavioral disruption—overstates its scope. Population surveys report somatic symptoms like and breast tenderness as most prevalent, affecting 75-85% of menstruating women mildly, while severe dysphoric variants (PMDD) occur in 3-8%, linked to serotonin dysregulation rather than blanket irrationality. Double-blind trials confirm symptom cyclicity tied to luteal-phase progesterone withdrawal, not fabrication, though sociocultural amplification can inflate perceived mood impacts beyond hormonal causality alone.

Controversies in Modern Interpretations

Modern interpretations of the menstrual cycle have sparked debates over its influence on cognitive and emotional function, with meta-analyses indicating no substantial phase-related differences in cognitive performance such as , , or executive function across cycles in healthy women. Reviews of and behavioral data further suggest that while emotional processing and responses may fluctuate due to and progesterone variations, these effects are modest compared to inter-individual variability and do not support of cycle-driven . Such findings challenge earlier anecdotal claims and cultural narratives exaggerating cognitive impairments, attributing persistent myths to rather than empirical replication. Cycle syncing, a contemporary practice advocating tailored exercise, diet, and productivity based on cycle phases—such as high-intensity workouts during the and rest during —lacks robust scientific backing. Umbrella reviews of performance studies report inconsistent or negligible differences in strength, , or aerobic capacity between phases, with hormonal fluctuations exerting minimal impact on athletic output in trained women. Experts critique the trend as an oversimplification that risks promoting unsubstantiated wellness marketing over evidence-based training, noting that individual variability in symptoms like far outweighs predictable phase effects. Despite anecdotal reports of mood benefits from 43% of adherents, controlled trials do not substantiate broad recommendations, highlighting how amplification outpaces peer-reviewed validation. Premenstrual dysphoric disorder (PMDD), affecting 3-8% of menstruating women with severe mood disruptions tied to shifts, has faced contention between biological and sociocultural explanations. Critics in the 1980s-1990s argued PMDD pathologized normal emotional variability or reflected societal pressures, but genetic studies reveal altered regulation and sensitivity in affected individuals, confirming a neurobiological basis independent of behavioral . Diagnostic criteria require prospective symptom tracking to distinguish from comorbidities like major depression, countering earlier dismissals as psychosomatic; treatments targeting progesterone metabolites, such as selective serotonin inhibitors, yield response rates up to 70% in randomized trials. This shift underscores how ideological resistance delayed recognition, despite evidence from twin studies estimating 50-60% . Debates on menstrual suppression via continuous question its long-term safety against claims of . In pre-modern eras, women experienced 50-100 fewer cycles due to pregnancies and , reducing endometrial exposure; modern repetitive shedding correlates with elevated risks of and gynecological disorders in observational data. While suppression achieves amenorrhea in 60-80% of users with combined pills, breakthrough bleeding occurs in up to 20%, and uncertainties persist regarding loss, cardiovascular events, and recovery post-use, particularly in adolescents. Proponents cite reduced and quality-of-life gains, yet cohort studies link prolonged to potential oncogenic shifts, though causal links remain unproven in RCTs; this tension reflects trade-offs between convenience and untested deviations from natural cyclicity.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK500020/
  2. https://www.ncbi.nlm.nih.gov/books/NBK279054/
  3. https://www.mayoclinic.org/healthy-lifestyle/womens-health/in-depth/menstrual-cycle/art-20047186/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7381001/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC8631146/
  6. https://pubmed.ncbi.nlm.nih.gov/29763196/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC2913133/
  8. https://www.nichd.nih.gov/health/topics/factsheets/menstruation
  9. https://pubmed.ncbi.nlm.nih.gov/29530426/
  10. https://www.ncbi.nlm.nih.gov/books/NBK537132/
  11. https://www.nature.com/articles/s41746-019-0152-7
  12. https://www.jognn.org/article/S0884-2175%2815%2934376-8/fulltext
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10226714/
  14. https://www.medrxiv.org/content/10.1101/2022.09.30.22280382v1
  15. https://www.sciencedirect.com/science/article/pii/S0015028207041386
  16. https://www.yourperiod.ca/normal-periods/menstrual-cycle-basics/
  17. https://academic.oup.com/humrep/article/39/11/2565/7775370
  18. https://www.ncbi.nlm.nih.gov/books/NBK279070/
  19. https://www.glowm.com/section-view/heading/The%20Hypothalamic-Hypophyseal-Ovarian%20Axis%20and%20the%20Menstrual%20Cycle/item/282
  20. https://academic.oup.com/humupd/article/12/5/557/776661
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4594618/
  22. https://www.nhs.uk/conditions/periods/fertility-in-the-menstrual-cycle/
  23. https://my.clevelandclinic.org/health/articles/10132-menstrual-cycle
  24. https://www.mayoclinic.org/healthy-lifestyle/womens-health/in-depth/menstrual-cycle/art-20047186
  25. https://www.acog.org/womens-health/faqs/heavy-and-abnormal-periods
  26. https://www.ncbi.nlm.nih.gov/books/NBK542229/
  27. https://www.ucsfhealth.org/education/the-menstrual-cycle
  28. https://www.ncbi.nlm.nih.gov/books/NBK441996/
  29. https://www.reproductivefacts.org/news-and-publications/fact-sheets-and-infographics/am-i-ovulating/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC5689497/
  31. https://www.ncbi.nlm.nih.gov/books/NBK539704/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4436586/
  33. https://www.healthline.com/health/how-late-can-a-period-be
  34. https://my.clevelandclinic.org/health/diseases/14633-abnormal-menstruation-periods
  35. https://www.ncbi.nlm.nih.gov/books/NBK549773/
  36. https://https://www.ncbi.nlm.nih.gov/books/NBK500020/
  37. https://https://www.ncbi.nlm.nih.gov/books/NBK549773/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4546331/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC3763969/
  40. https://my.clevelandclinic.org/health/diseases/21698-anovulation
  41. https://emedicine.medscape.com/article/253190-overview
  42. https://www.osmosis.org/answers/anovulatory-cycle
  43. https://fertility.womenandinfants.org/services/women/anovulation
  44. https://www.healthline.com/health/pregnancy/anovulatory-cycle
  45. https://academic.oup.com/jcem/article/83/12/4220/2865336
  46. https://emedicine.medscape.com/article/253190-treatment
  47. https://www.merckmanuals.com/professional/gynecology-and-obstetrics/infertility-and-recurrent-pregnancy-loss/ovulatory-dysfunction
  48. https://www.asrm.org/practice-guidance/practice-committee-documents/diagnosis-and-treatment-of-luteal-phase-deciency-a-committee-opinion-2021/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4037737/
  50. https://www.fertstert.org/article/S0015-0282%2821%2900128-X/fulltext
  51. https://www.sciencedirect.com/science/article/pii/S0015028216630224
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5337433/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3659905/
  54. https://progyny.com/education/female-infertility/luteal-phase-deficiency/
  55. https://my.clevelandclinic.org/health/diseases/luteal-phase-defect
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC9964744/
  57. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
  58. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-025-01621-6
  59. https://www.imrpress.com/journal/CEOG/51/12/10.31083/j.ceog5112269/htm
  60. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.873726/full
  61. https://bmjmedicine.bmj.com/content/2/1/e000548
  62. https://www.who.int/news-room/fact-sheets/detail/endometriosis
  63. https://www.nejm.org/doi/full/10.1056/NEJMra1810764
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC4782879/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC9580640/
  66. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1328403/full
  67. https://www.ncbi.nlm.nih.gov/books/NBK459251/
  68. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-22881-3
  69. https://academic.oup.com/jcem/article/110/7/e2298/7965891
  70. https://pubmed.ncbi.nlm.nih.gov/33199360/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC8906247/
  72. https://www.aafp.org/pubs/afp/issues/2016/0801/p236.html
  73. https://psychiatryonline.org/doi/10.1176/ajp.154.12.1741
  74. https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-021-01374-6
  75. https://www.nature.com/articles/s41598-025-02459-0
  76. https://www.ox.ac.uk/news/2024-01-30-new-data-shows-prevalence-premenstrual-dysphoric-disorder
  77. https://www.nature.com/articles/s41593-025-02066-2
  78. https://www.nature.com/articles/s44294-024-00012-4
  79. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2015.00044/full
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC4241821/
  81. https://uclacns.org/the-close-link-between-the-brain-and-the-menstrual-cycle/
  82. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0318576
  83. https://www.sciencedirect.com/science/article/abs/pii/S0083672918300165
  84. https://www.mdpi.com/2079-7737/14/8/1060
  85. https://www.sciencedirect.com/science/article/pii/S0166432821004812
  86. https://www.nichd.nih.gov/about/org/od/directors_corner/prev_updates/menstrual-cycles
  87. https://pubmed.ncbi.nlm.nih.gov/39906529/
  88. https://www.bmj.com/content/371/bmj.m3464
  89. https://www.ahajournals.org/doi/10.1161/JAHA.122.029020
  90. https://hsph.harvard.edu/news/irregular-periods-linked-with-increased-risk-for-cardiometabolic-conditions/
  91. https://pubmed.ncbi.nlm.nih.gov/38130524/
  92. https://www.sciencedirect.com/science/article/abs/pii/S2666571924000380
  93. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819142
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC8162175/
  95. https://www.ncbi.nlm.nih.gov/books/NBK430882/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC7365466/
  97. https://pubmed.ncbi.nlm.nih.gov/10561657/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC10979803/
  99. https://pubmed.ncbi.nlm.nih.gov/8178900/
  100. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.12036
  101. https://www.aafp.org/pubs/afp/issues/2002/0515/p2073.html
  102. https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet
  103. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788119
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC9867809/
  105. https://www.uclahealth.org/news/release/study-shows-how-birth-control-pills-affect-womens
  106. https://www.sciencedirect.com/science/article/pii/S1521693424001202
  107. https://pubmed.ncbi.nlm.nih.gov/35029663/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC5102181/
  109. https://www.ncbi.nlm.nih.gov/books/NBK546661/
  110. https://www.mayoclinic.org/tests-procedures/basal-body-temperature/about/pac-20393026
  111. https://my.clevelandclinic.org/health/articles/21065-basal-body-temperature
  112. https://my.clevelandclinic.org/health/body/21957-cervical-mucus
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC11837971/
  114. https://www.ncbi.nlm.nih.gov/books/NBK564316/
  115. https://academic.oup.com/humrep/article/22/5/1310/2914315
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC4807745/
  117. https://www.cureus.com/articles/376697-fertility-awareness-based-methods-for-family-planning-a-systematic-review
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC9171018/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC8917888/
  120. https://pubmed.ncbi.nlm.nih.gov/27390383/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC3528014/
  122. https://www.scientificamerican.com/article/what-is-the-point-of-a-period/
  123. https://www.journals.uchicago.edu/doi/abs/10.1086/418170
  124. https://pubmed.ncbi.nlm.nih.gov/8693059/
  125. https://www.journals.uchicago.edu/doi/abs/10.1086/204592
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC7334061/
  127. https://academic.oup.com/biolreprod/article/102/6/1160/5775593
  128. https://www.sciencedirect.com/science/article/pii/S0093691X18302796
  129. https://www.sciencedirect.com/science/article/abs/pii/S0047637403001349
  130. https://www.nature.com/articles/nature.2016.20072
  131. https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2021.784578/full
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC6541669/
  133. https://www.science.org/content/article/lab-mice-can-now-have-periods-humans
  134. https://pubmed.ncbi.nlm.nih.gov/1287678/
  135. https://www.researchgate.net/publication/225181786_Menstrual_synchrony_Fact_or_artifact
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC10771221/
  137. https://qz.com/1706398/the-average-menstrual-cycle-is-not-28-days
  138. https://hsph.harvard.edu/research/apple-womens-health-study/study-updates/menstrual-cycles-today-how-menstrual-cycles-vary-by-age-weight-race-and-ethnicity/
  139. https://www.sciencealert.com/menstrual-cycles-dont-affect-womens-cognitive-abilities-study-finds
  140. https://www.technologynetworks.com/neuroscience/news/the-menstrual-cycle-and-cognition-what-the-science-really-says-397772
  141. https://www.ncbi.nlm.nih.gov/books/NBK565629/
  142. https://www.iflscience.com/periods-dont-affect-your-cognitive-skills-new-study-busts-another-menstruation-myth-72784
  143. https://psychiatryonline.org/doi/pdf/10.1176/ps.46.11.1199?download=true
  144. https://www.jeanhailes.org.au/news/pms-premenstrual-syndrome-fact-versus-fiction
  145. https://www.nature.com/articles/s41386-019-0435-3
  146. https://www.apa.org/news/podcasts/speaking-of-psychology/menstrual-cycle
  147. https://pmc.ncbi.nlm.nih.gov/articles/PMC10076834/
  148. https://time.com/6315797/cycle-syncing-womens-heath/
  149. https://www.tomsguide.com/wellness/fitness/top-experts-debunk-the-cycle-syncing-trend-the-evidence-just-isnt-there
  150. https://www.womenshealthmag.com/uk/fitness/a65896825/cycle-syncing-exercise/
  151. https://pmc.ncbi.nlm.nih.gov/articles/PMC9564553/
  152. https://www.health.harvard.edu/blog/premenstrual-dysphoria-disorder-its-biology-not-a-behavior-choice-2017053011768
  153. https://www.apa.org/monitor/oct02/pmdd
  154. https://pmc.ncbi.nlm.nih.gov/articles/PMC2992541/
  155. https://www.sciencedirect.com/science/article/abs/pii/S0306987720312445
  156. https://pmc.ncbi.nlm.nih.gov/articles/PMC4075955/
  157. https://www.ncbi.nlm.nih.gov/books/NBK592411/
  158. https://www.nature.com/news/2006/061211/full/news061211-8.html
Add your contribution
Related Hubs
User Avatar
No comments yet.